Pittsburgh woman’s advocacy leads to statewide Gaucher screening
HealthThe disease disproportionately affects Ashkenazi Jews

Pittsburgh woman’s advocacy leads to statewide Gaucher screening

Early diagnosis is essential to prevent, or slow, the most serious outcomes

Aviva Rosenberg (at podium behind mic) stands with state Rep. Dan Frankel (front row, second from right) and state Rep. Abigail Salisbury (front row, far right) and other advocates for House Bill 1652. (Photo courtesy of Aviva Rosenberg)
Aviva Rosenberg (at podium behind mic) stands with state Rep. Dan Frankel (front row, second from right) and state Rep. Abigail Salisbury (front row, far right) and other advocates for House Bill 1652. (Photo courtesy of Aviva Rosenberg)

Growing up in Chicago, Aviva Rosenberg frequently suffered nose bleeds, anemia and broken bones, only to be told by pediatricians to eat more chopped liver and red meat.

During law school, the low platelet count in her blood was dismissed as “pretty common,” she said. “Not a big deal.”
It wasn’t until Rosenberg and her husband, Dr. Pinchas Rosenberg, were planning a family that she learned, through genetic testing, that the cause of her various maladies was Gaucher disease, a rare, inherited condition that can cause severe, even fatal, health issues, and is disproportionately prevalent among Ashkenazi Jews.

“Gaucher is the most common Jewish genetic disease,” said Rosenberg, 49, a Squirrel Hill mother of three sons, who cofounded the Gaucher Community Alliance in 2019.

“It affects one in about 750 Ashkenazi Jews compared to one in 50,000 people in the general population. Israel has one of the highest incidence rates of Gaucher disease per capita in the world.”

Because early diagnosis is essential to prevent, or slow, the most serious outcomes, Rosenberg has spent the last three years lobbying Harrisburg to add Gaucher disease to the dozens of other serious, treatable conditions for which infants are routinely tested soon after birth.

As a result, House Bill 1652 was passed and signed into law as Act 73 of 2026 on Oct. 22. It will take effect in 2027.

“This was truly a team effort and we are so grateful,” said Aviva Rosenberg, who credits state Rep. Abigail Salisbury (D-34) for introducing the legislation, State Rep. Dan Frankel (D-23) as chair of the House Health Committee, and the Beacon Coalition, a group that protects the well-being and rights of Jews, for its support.

Aviva Rosenberg was accompanied on at least one trip to Harrisburg by a friend, pediatrician Dr. Kenneth Levin, of Squirrel Hill, who helped make the case for early routine Gaucher screening.

“Otherwise, how could you ever justify to a family that if their child had been tested as a newborn they would have known and been able to prepare for treatment,” he said. “It’s going to save a few lives every year.”

Pronounced “go-shay” and named for the French physician who first described it in 1882, Gaucher disease results when the body is missing an enzyme — GCase — needed to break down certain fatty substances. Cells normally have tiny structures called lysosomes that clear away waste. When GCase is missing or malfunctioning, fatty substances accumulate in the body’s cells. Over time, this can lead to an enlarged liver or spleen, anemia, easy bruising, bone and lung issues, fatigue, and, in some cases, seizures and other brain and central nervous system problems.

There are three types of Gaucher. The majority of Jews with Gaucher have type 1, which typically does not affect the nervous system, but does increase the risk of developing Parkinson’s disease, Aviva Rosenberg said, noting type 1 is more common in the Western world across all demographics.

Type 2 is a severe, rapidly worsening condition that begins in infancy, affects the central nervous system and usually results in death by early childhood, while type 3 is a chronic, slower-progressing neuronopathic form that typically is diagnosed around age 2 without newborn screening, Aviva Rosenberg said.

“There are no FDA-approved treatments to slow the progression of type 2 but some babies can receive off-label therapies to improve the quality of their life. With type 3, if treatment starts within weeks of birth, children have a greater chance of living full productive lives.”

In her work with the Gaucher Community Alliance, Aviva Rosenberg said she has heard “very sad, really heartbreaking stories” of children and adults being misdiagnosed with — and mistakenly treated for — other illnesses, because they were not tested for Gaucher.

“A 5-year-old in Texas was operated on for what was believed to be an infection in his femur,” Aviva Rosenberg said. “I’ve heard about 12-year-olds needing hip replacements. A guy in New York just thought he was really sleepy all the time. A Wisconsin child was sent for an autism evaluation.

“Families can be traumatized.”

Because they had a Jewish fertility doctor, Rachel and Kevin Schmerling of Chester Springs, Pennsylvania, knew they were carriers of Gaucher when Rachel became pregnant with Juliana, the first of their four children, 17 years ago.

But trying to convince the hospital to test her became “a nightmare,” Rachel Schmerling said. “Nobody knew how to make that happen. It became this huge deal that wasted so much time.”

The Schmerlings took their daughter for testing a month later at a different clinic and she was found to be carrying the Gaucher gene.

They took their second child, Jacob, now 15, to the same clinic where he tested positive for Gaucher type 1. He began receiving twice-monthly IV enzyme replacement infusions when he was 3 years old that continue today. They help him to enjoy life like any other teen, his father said, noting that Jacob plays ice hockey, rugby and lacrosse.

Because the Schmerlings were knowledgeable about Gaucher and proactive, “Jacob is one of the lucky few,” Kevin Schmerling said.

Infusions are the standard protocol for Gaucher types 1 and 3, although some type 1 patients can instead receive oral substrate reduction therapy. However, neither treatment can cross the blood-brain barrier to address neurological symptoms.

A major advancement in that regard occurred Nov. 18 when the FDA approved a new oral therapy, Infilbray, that does cross the blood-brain barrier, providing new hope for type 3 patients.

While the Gaucher Community Alliance scored a major victory in Pennsylvania, its fight is far from over. The Alliance is working with half a dozen states to get newborn Gaucher screening implemented, Aviva Rosenberg said, noting that just 11 states currently have such testing in place or in process. PJC

Deborah Weisberg is a freelance writer living in Pittsburgh.

read more:
comments